Literature DB >> 24861084

Lipid biology of the podocyte--new perspectives offer new opportunities.

Alessia Fornoni1, Sandra Merscher1, Jeffrey B Kopp2.   

Abstract

In the past 15 years, major advances have been made in understanding the role of lipids in podocyte biology. First, susceptibility to focal segmental glomerulosclerosis (FSGS) and glomerular disease is associated with an APOL1 sequence variant, is expressed in podocytes and encodes apolipoprotein L1, an important component of HDL. Second, acid sphingomyelinase-like phosphodiesterase 3b encoded by SMPDL3b has a role in the conversion of sphingomyelin to ceramide and its levels are reduced in renal biopsy samples from patients with recurrent FSGS. Furthermore, decreased SMPDL3b expression is associated with increased susceptibility of podocytes to injury after exposure to sera from these patients. Third, in many individuals with membranous nephropathy, autoantibodies against the phospholipase A2 (PLA2) receptor, which is expressed in podocytes, have been identified. Whether these autoantibodies affect the activity of PLA2, which liberates arachidonic acid from glycerophospholipids and modulates podocyte function, is unknown. Fourth, clinical and experimental evidence support a role for ATP-binding cassette sub-family A member 1-dependent cholesterol efflux, free fatty acids and glycerophospolipids in the pathogenesis of diabetic kidney disease. An improved understanding of lipid biology in podocytes might provide insights to develop therapeutic targets for primary and secondary glomerulopathies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24861084      PMCID: PMC4386893          DOI: 10.1038/nrneph.2014.87

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  141 in total

1.  Cellular cholesterol efflux to serum is impaired in diabetic nephropathy.

Authors:  Huali Zhou; Kathryn C B Tan; Sammy W M Shiu; Ying Wong
Journal:  Diabetes Metab Res Rev       Date:  2008 Nov-Dec       Impact factor: 4.876

2.  Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.

Authors:  Monika A Niewczas; Tomohito Gohda; Jan Skupien; Adam M Smiles; William H Walker; Florencia Rosetti; Xavier Cullere; John H Eckfeldt; Alessandro Doria; Tanya N Mayadas; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2012-01-19       Impact factor: 10.121

3.  Possible induction of renal dysfunction in patients with lecithin:cholesterol acyltransferase deficiency by oxidized phosphatidylcholine in glomeruli.

Authors:  S Jimi; N Uesugi; K Saku; H Itabe; B Zhang; K Arakawa; S Takebayashi
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

Review 4.  Defective cholesterol trafficking in Niemann-Pick C-deficient cells.

Authors:  Kyle B Peake; Jean E Vance
Journal:  FEBS Lett       Date:  2010-04-21       Impact factor: 4.124

5.  Insulin resistance in insulin-dependent diabetic patients with microalbuminuria.

Authors:  J Yip; M B Mattock; A Morocutti; M Sethi; R Trevisan; G Viberti
Journal:  Lancet       Date:  1993-10-09       Impact factor: 79.321

6.  Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function.

Authors:  Jing Jin; Karen Sison; Chengjin Li; Ruijun Tian; Monika Wnuk; Hoon-Ki Sung; Marie Jeansson; Cunjie Zhang; Monika Tucholska; Nina Jones; Dontscho Kerjaschki; Masabumi Shibuya; I George Fantus; Andras Nagy; Hans-Peter Gerber; Napoleone Ferrara; Tony Pawson; Susan E Quaggin
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

7.  Renal involvement in adult Gaucher's disease after splenectomy.

Authors:  P N Chander; H M Nurse; C L Pirani
Journal:  Arch Pathol Lab Med       Date:  1979-08       Impact factor: 5.534

8.  Apoptosis in the kidneys of patients with type II diabetic nephropathy.

Authors:  D Verzola; M T Gandolfo; F Ferrario; M P Rastaldi; B Villaggio; F Gianiorio; M Giannoni; L Rimoldi; F Lauria; M Miji; G Deferrari; G Garibotto
Journal:  Kidney Int       Date:  2007-09-12       Impact factor: 10.612

9.  ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death.

Authors:  Siqin Zhaorigetu; Guanghua Wan; Ramesh Kaini; Zeyu Jiang; Chien-an A Hu
Journal:  Autophagy       Date:  2008-11-23       Impact factor: 16.016

10.  Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Valentine Charlton-Menys; David A DeMicco; John H Fuller
Journal:  Am J Kidney Dis       Date:  2009-06-21       Impact factor: 8.860

View more
  53 in total

1.  A kidney-specific genome-scale metabolic network model for analyzing focal segmental glomerulosclerosis.

Authors:  Salma Sohrabi-Jahromi; Sayed-Amir Marashi; Shiva Kalantari
Journal:  Mamm Genome       Date:  2016-02-29       Impact factor: 2.957

Review 2.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

3.  Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.

Authors:  Justin Chun; Jia-Yue Zhang; Maris S Wilkins; Balajikarthick Subramanian; Cristian Riella; Jose M Magraner; Seth L Alper; David J Friedman; Martin R Pollak
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-07       Impact factor: 11.205

4.  Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.

Authors:  Christopher E Pedigo; Gloria Michelle Ducasa; Farah Leclercq; Alexis Sloan; Alla Mitrofanova; Tahreem Hashmi; Judith Molina-David; Mengyuan Ge; Mariann I Lassenius; Carol Forsblom; Markku Lehto; Per-Henrik Groop; Matthias Kretzler; Sean Eddy; Sebastian Martini; Heather Reich; Patricia Wahl; GianMarco Ghiggeri; Christian Faul; George W Burke; Oliver Kretz; Tobias B Huber; Armando J Mendez; Sandra Merscher; Alessia Fornoni
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

5.  Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.

Authors:  Teresa K Chen; Michael J Choi; W H Linda Kao; Brad C Astor; Julia J Scialla; Lawrence J Appel; Liang Li; Michael S Lipkowitz; Myles Wolf; Rulan S Parekh; Cheryl A Winkler; Michelle M Estrella; Deidra C Crews
Journal:  Clin J Am Soc Nephrol       Date:  2015-10-01       Impact factor: 8.237

Review 6.  Systemic and renal lipids in kidney disease development and progression.

Authors:  Patricia Wahl; Gloria Michelle Ducasa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-23

7.  ApoL1 renal risk variants induce aberrant THP-1 monocyte differentiation and increase eicosanoid production via enhanced expression of cyclooxygenase-2.

Authors:  Hewang Lee; Hila Roshanravan; Ying Wang; Koji Okamoto; Junghwa Ryu; Shashi Shrivastav; Peng Qu; Jeffrey B Kopp
Journal:  Am J Physiol Renal Physiol       Date:  2018-01-10

8.  Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia.

Authors:  Kosuke Sawami; Atsushi Tanaka; Tsukasa Nakamura; Eiichi Sato; Yoshihiko Ueda; Koichi Node
Journal:  J Cardiol Cases       Date:  2018-03-19

Review 9.  Lipotoxicity as a trigger factor of renal disease.

Authors:  Adriana Izquierdo-Lahuerta; Cristina Martínez-García; Gema Medina-Gómez
Journal:  J Nephrol       Date:  2016-03-08       Impact factor: 3.902

10.  Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial.

Authors:  Gabor Bodonyi-Kovacs; Jennie Z Ma; Jamison Chang; Michael S Lipkowitz; Jeffrey B Kopp; Cheryl Ann Winkler; Thu H Le
Journal:  J Am Soc Nephrol       Date:  2016-03-03       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.